Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis ameliorated by folate supplement

Jun-Ichi Fukushi, Yasuharu Nakashima, Yukihide Iwamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 62-year-old male with a 10-year history of seropositive rheumatoid arthritis (RA) developed gynecomastia 8 months after beginning oral low-dose methotrexate (MTX) therapy. Two months after folate supplementation, the gynecomastia symptoms improved. Gynecomastia associated with low-dose MTX is a rare occurrence, with only nine cases previously reported in the literature. This is the first report showing folate supplementation to be effective against gynecomastia following low-dose MTX. Although it occurs infrequently, gynecomastia associated with low-dose MTX therapy should be considered in male patients with RA.

Original languageEnglish
Pages (from-to)1371-1372
Number of pages2
JournalRheumatology International
Volume30
Issue number10
DOIs
Publication statusPublished - Aug 1 2010

Fingerprint

Gynecomastia
Folic Acid
Methotrexate
Rheumatoid Arthritis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis ameliorated by folate supplement. / Fukushi, Jun-Ichi; Nakashima, Yasuharu; Iwamoto, Yukihide.

In: Rheumatology International, Vol. 30, No. 10, 01.08.2010, p. 1371-1372.

Research output: Contribution to journalArticle

@article{0d5f96f993434a52a63abccecb7a42e2,
title = "Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis ameliorated by folate supplement",
abstract = "A 62-year-old male with a 10-year history of seropositive rheumatoid arthritis (RA) developed gynecomastia 8 months after beginning oral low-dose methotrexate (MTX) therapy. Two months after folate supplementation, the gynecomastia symptoms improved. Gynecomastia associated with low-dose MTX is a rare occurrence, with only nine cases previously reported in the literature. This is the first report showing folate supplementation to be effective against gynecomastia following low-dose MTX. Although it occurs infrequently, gynecomastia associated with low-dose MTX therapy should be considered in male patients with RA.",
author = "Jun-Ichi Fukushi and Yasuharu Nakashima and Yukihide Iwamoto",
year = "2010",
month = "8",
day = "1",
doi = "10.1007/s00296-009-1062-9",
language = "English",
volume = "30",
pages = "1371--1372",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis ameliorated by folate supplement

AU - Fukushi, Jun-Ichi

AU - Nakashima, Yasuharu

AU - Iwamoto, Yukihide

PY - 2010/8/1

Y1 - 2010/8/1

N2 - A 62-year-old male with a 10-year history of seropositive rheumatoid arthritis (RA) developed gynecomastia 8 months after beginning oral low-dose methotrexate (MTX) therapy. Two months after folate supplementation, the gynecomastia symptoms improved. Gynecomastia associated with low-dose MTX is a rare occurrence, with only nine cases previously reported in the literature. This is the first report showing folate supplementation to be effective against gynecomastia following low-dose MTX. Although it occurs infrequently, gynecomastia associated with low-dose MTX therapy should be considered in male patients with RA.

AB - A 62-year-old male with a 10-year history of seropositive rheumatoid arthritis (RA) developed gynecomastia 8 months after beginning oral low-dose methotrexate (MTX) therapy. Two months after folate supplementation, the gynecomastia symptoms improved. Gynecomastia associated with low-dose MTX is a rare occurrence, with only nine cases previously reported in the literature. This is the first report showing folate supplementation to be effective against gynecomastia following low-dose MTX. Although it occurs infrequently, gynecomastia associated with low-dose MTX therapy should be considered in male patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=77955549922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955549922&partnerID=8YFLogxK

U2 - 10.1007/s00296-009-1062-9

DO - 10.1007/s00296-009-1062-9

M3 - Article

C2 - 19597731

AN - SCOPUS:77955549922

VL - 30

SP - 1371

EP - 1372

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 10

ER -